Piper Sandler raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $13 from $11 and keeps an Overweight rating on the shares. The firm notes Amneal reported Q3 adjusted diluted EPS of 17c on revenue of $784.5M, compared to Street estimates of 14c and $773.9M, respectively.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals Reports Strong Q3 2025 Results
- Amneal Pharmaceuticals reports Q3 adjusted EPS 17c, consensus 14c
- Amneal Pharmaceuticals raises 2025 adjusted EPS view to 75c-80c from 70c-75c
- Amneal gets FDA approval for beclomethasone dipropionate HFA inhalation aerosol
- Mycophenolate Pregnancy Registry: Key Insights for Investors